Harmony-HHT

Do you or does someone you know have HHT?

We are seeking volunteers to participate in a Phase 1/2 clinical study.
group of people
Explore a new approach that could change the future of HHT treatment and improve the lives of generations to come.

Harmony-HHT: 


A Clinical Trial for an Investigational AKT1 Inhibitor in Hereditary Hemorrhagic Telangiectasia (HHT)

Learn More

About HHT

  • Hereditary Hemorrhagic Telangiectasia (HHT) is a genetically inherited disease that causes malformed blood vessels and can affect multiple systems in the body.
  • HHT can cause bleeding and long-term damage to several organs of the body. The most commonly experienced symptom is nosebleeds that can vary in severity. Other commonly affected organs are the gastrointestinal (GI) tract, liver, lungs, and brain.
  • AKT1 is a protein that is hyperactivated in HHT and contributes to disorganized cell growth and the formation of abnormal blood vessels (AVMs), which can rupture or cause abnormal blood flow leading to chronic bleeding, anemia, organ damage, and for some, life-threatening complications.

What is the Harmony-HHT study?

The Harmony-HHT study is evaluating the safety and efficacy of ATV-1601 to determine if it can improve symptoms and potentially address the underlying disease for individuals with moderate to severe HHT.

What is ATV-1601?

ATV-1601 is an oral selective allosteric AKT1 inhibitor that has the potential to address all HHT-driving mutations and improve clinical outcomes for individuals with HHT.

For more details, visit ClinicalTrials.gov NCT07601425

Can I participate?

  • At least 18 years old
  • Diagnosed with HHT and have moderate to severe HHT characterized by frequent nose
bleeds that are hard to control
  • Have anemia and/or received treatment for anemia
  • Generally healthy without other chronic health problems

If you would like to learn more about this study, 
CONTACT US

man walking dog

Clinical Trial Disclosure
This clinical trial is conducted in accordance with regulatory guidelines and approved by ethics review boards. The investigational drug has not yet been approved by the FDA or other regulatory agencies for the treatment of HHT.